by B2i | Jun 28, 2021 | Press Releases
Dyadic’s C1-cell protein production platform selected as a fast response vaccine manufacturing model against zoonotic diseases.C1...
by B2i | May 26, 2021 | Press Releases
In collaboration with Syngene International Ltd.JUPITER, Fla., May 26, 2021 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its...
by B2i | May 24, 2021 | Press Releases
JUPITER, FL / May 24, 2021 / Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to...
by B2i | May 13, 2021 | Press Releases
Advancing Dyadic’s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial Goal of validating that C1 produced proteins are safe in humans and to accelerate adoption and use of C1 technology platform for the development...
by B2i | May 3, 2021 | Press Releases
JUPITER, Fla., May 03, 2021 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform...
by B2i | Apr 29, 2021 | Press Releases
JUPITER, FL / April 29, 2021 / Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its...
